NHS-Galleri Trial Clinical
hero image

Detecting cancer early in the United Kingdom 

The NHS-Galleri Study is investigating the clinical and economic performance of the Galleri™ test in the United Kingdom’s National Health Service (NHS). Results from the trial will help determine if Galleri becomes part of routine cancer screening by the NHS.

The study will initially enroll 140,000 people aged 50 to 77 in the United Kingdom.

Galleri: GRAIL’s multi-cancer early detection test

The Galleri test can detect multiple types of cancer through a single blood draw by looking for signals of cancer that may be present. If a signal that may be cancer is detected, Galleri can identify the location of the cancer signal in the body, for example, the pancreas or the liver, with high accuracy. This information is intended to help healthcare providers determine the appropriate test(s) to confirm whether cancer is present.

Eligibility

The NHS-Galleri Study is open for enrollment by NHS invitation. NHS will invite 140,000 volunteers aged 50-77, who have not been diagnosed or treated for cancer in the last three years and live in one of the areas where the trial is active.

Current Status:
Enrolling
Collaborators
collaborator
collaborator
collaborator